VeriSIM Life的动态

If you've ever heard Ricki Fairley talk, you know this is sure to be a great panel. Looking forward to hearing your insights, and better understanding how we can provide better support, care, and empathy. #ClinicalTrials #Patients #Diversity #ListenToUnderstand

If you've engaged with our commercial team, you may have worked with Jocelyn Foye, Sr. Manager of Business Development, Antibodies, North America. She enjoys connecting with customers and talking about Fortis and our solutions for life sciences and diagnostics. Learn more about Jocelyn in this feature for Women's History Month! #WomensHistoryMonth #WomensHistoryMonth2024 #seeher #womeninscience #womeninstem #antibodyresearch #antibodyconjugation #InternationalWomensDay

? Strategic Placement ? #Orthocell has today announced that it has completed a Company-led Strategic Placement to raise $3.5 million. ? The Company welcomes prominent investors Mr Chris Ellison, Mr Rod Jones, Mr Michael Malone, the McCusker Family and the Merchant Biotech Fund, which significantly strengthens the Company’s share register. ? With the strategic placement now complete, the Company is well funded to execute its global market expansion strategy and the pivotal US product registration for Remplir?, expected in Q1 CY24 ? Orthocell Chair, John Van Der Wielen, said: ? “The support of these strategic investors is an endorsement of Orthocell’s science, business strategy and progress in commercialising its leading bone and nerve repair products, and the exciting outlook for the Company as it progresses approvals in new key jurisdictions like the US. The Board and I would like to welcome the new investors to the register.” ? Read today’s ASX release ?? https://lnkd.in/gg89rcai $OCC #biotech #regenerativemedicine #medicaldevice #healthcare #innovation #placement #ASX

The saga surrounding Illumina's acquisition of Grail is a troubling reflection of the current regulatory climate. Due to aggressive antitrust measures, Illumina was forced to divest Grail, a pioneering company in multi-cancer early detection. Grail's technology, which can identify up to 50 types of cancer from a single drop of blood, is a potential game-changer in the fight against cancer—a fight where early detection is often the key to survival. However, separated from Illumina, a global leader in genome sequencing with the financial strength to support such innovation, Grail is now struggling, like many biotech firms in today’s high-interest-rate environment. As a standalone entity, Grail is compelled to operate in a capital-conserving mode, delaying the commercialization of its life-saving technology. This heavy-handed regulatory approach to antitrust in the tech sector is often counterproductive. By restricting acquisitions of innovative startups by larger tech firms, regulators are inadvertently stifling innovation and competitiveness. They are cutting off vital funding for startups and eliminating crucial exit options for early-stage investors, ultimately hampering the development of breakthrough technologies that could save lives.

In today's competitive business landscape, fostering a culture of innovation is crucial for success. This is particularly the case in the healthcare and pharmaceutical fields. But where do the best ideas come from? According to Merck, a key driver is a diverse workforce. Merck highlights how diversity brings forth a variety of perspectives, enhances problem-solving, and improves decision-making. One of the keys to capturing the full potential of your diverse team is fostering open communication. Next-gen software tools are making that goal more accessible than ever. If you're looking to enhance collaboration and ensure that your team's best ideas are not only captured but appropriately credited, InspireIP can help. Contact us today ([email protected]) to find out how we can help you capitalize on the wide range of perspectives your team brings to build an unparalleled culture of innovation! #Innovation #CultureOfInnovation #Diversity #Inclusion https://lnkd.in/gCxUjJuN

My experience nearly 25 years ago as a research coordinator for a clinical trial in lung cancer made me realize that patients deserve better, and I vowed to amplify patients’ voices and dedicated my career to improving drug development. In pharma, I had the privilege to work on the dawn of immunotherapy in lung cancer. With patients surviving longer with these therapies, I felt I was able to make a difference. When my son, Caffrey, was diagnosed with Duchenne muscular dystrophy, I was shocked that the standard of care today is still high dose steroids that do nothing to address the underlying genetic cause of the disease. I was even more disheartened when, after an exhaustive search of clinical trials, we found out that he was not eligible for a single one.? As a family, we felt marooned, alone, and really scared. I'm really at a loss to describe that sheer feeling of hopelessness and grief that comes when your child gets a catastrophic diagnosis. It can be all consuming and soul destroying. One of the first glimmers of hope during this time is when I found out about Alltrna. I immediately understood the potential of this platform and could see how Alltrna’s engineered tRNAs could be a lifeline for patients with thousands of genetic diseases and a lifeline for those families that love them. This was an opportunity for me to channel all my years in pharma and bring that drug development experience to those overlooked and underserved patient populations. In the last two decades, I can look back and feel like I've played a small but maybe a meaningful role in helping to advance the five year survival rates for many metastatic cancers and make those better. Can you imagine if in the next two decades, we can do the same for rare diseases? ??To do this, we need to first and foremost, lead with empathy, and always think about the patient at the center of what we do. ??We must drive innovation – don't wait for it to happen. We have to actively choose to make a difference in those bold choices that really make innovation matter. ??Take risks. Those safe bets aren't helping anyone. We have to take the risks to really make a difference for patients. ??Act with urgency – as if your kid's life depends on it. ??Really importantly, embrace who you are. ??At the end of the day, always, always, always remember patients deserve better.?

Don’t miss our March 2024 StarFish News & Insights featuring articles from our QA/RA team! This issue includes key regulatory trends in 2024, a comparison of medical device 510(k) and CE marking, the FDA’s real-world evidence draft guidance, and the impact of ESG on medical devices. #quality #regulatory #commercialization #medtech #medicaldevices

Happy Fourth of July ?? The Fourth of July commemorates the pivotal day when the United States declared its independence, a testament to the enduring values of freedom and democracy. It’s a celebration of the brave visionaries who paved the way for a nation built on liberty and opportunity. This day serves as a powerful reminder of the relentless pursuit of progress. This same spirit of innovation and progress is what drives the USA’s success in high-tech industries such as semiconductors and biopharma and life sciences. As Exyte grows in the USA, we're proud to play a significant role in these sectors, bringing the future of technology to life. On this occasion, we wish our colleagues, clients, and partners in the USA a happy and safe Fourth of July. Want to know more about Exyte in the USA? Discover these seven facts about our operations, teams, and subsidiaries: https://bit.ly/3RAStbB #Exyte #ExyteCareersAreExciting #FourthOfJuly #USA

It’s our 100th episode!! ?? To celebrate we have picked three technologies that are receiving traction right now - #FemTech #BatteryTech #Dementia - and are joined by AstraZeneca consultant, Stasa Stankovic; Dr. Simon Engelke, Founder and Chair of Battery Associates; and Andrew Kadis, Cambridge Vision Technology. Tune in to find out more about why the media is so interested in these areas. #CamTechPod

?? With RNA constantly changing and innovating, we thought we should too! A new take on your traditional conference showcase ?? If you're active in the RNA space (or a fan of shark tank ??), let's connect and have a chat #rna #biotech #investment #mrna #RNALeaders